Lung Cancer
(FURMO-004) A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations
- Details
ClinicalTrials.gov ID:
NCT05607550
Diagnosis Type:
NA
USOR Number:
- Address
480 Osborne Rd NE, Suite 220
Fridley, MN 55432
P: (763) 786-1620